mrd in myeloma
Published 4 years ago • 47 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
3:35
myeloma global trends: gross underestimation
-
3:05
identifying new therapeutic targets on the surfaceome of myeloma plasma cells with proteomics
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:17
immunotherapy | high impact topic (hit)
-
8:42
assessing mrd in multiple myeloma
-
2:44
myeloma qol through induction and maintenance
-
2:46
managing patients with high-risk myeloma
-
4:01
kenneth anderson: what are the next steps to a myeloma cure?
-
1:46
mrd: the most relevant prognostic factor in myeloma
-
1:53
the future of multiple myeloma treatment
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
1:10
immune dysregulation in myeloma and impact on disease progression
-
1:09
the efficacy & role of iberdomide in r/r multiple myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
1:42
hdac inhibitors in multiple myeloma
-
4:57
idecabtagene vicleucel for r/r myeloma
-
4:48
unmet needs in unfit/frail patients with multiple myeloma
-
1:57
the safety and efficacy of iberdomide for the treatment of multiple myeloma